Akili, Inc. (AKLI)
Jul 2, 2024 - AKLI was delisted (reason: acquired by Virtual Therapeutics)
0.433
+0.001 (0.25%)
Inactive · Last trade price on Jul 1, 2024
AKLI's stock price has decreased by -60.98% in the past year and price targets may not have had time to catch up.

Akili Analyst Ratings

Total Analysts
1
Consensus Rating
Buy
Price Target
$4.00
Upside
+823.57%

Ratings History

Analyst Firm Rating Rating Action Price Target Upside Date
Credit Suisse
Credit Suisse
Buy
Reiterates
$4
Buy Reiterates $4 +823.57% Aug 11, 2023
Morgan Stanley
Morgan Stanley
Hold
Maintains
$2$3
Hold Maintains $2$3 +592.68% Jan 25, 2023
Morgan Stanley
Morgan Stanley
Hold
Initiates
$2
Hold Initiates $2 +361.79% Dec 28, 2022
B of A Securities
B of A Securities
Hold
Initiates
$2
Hold Initiates $2 +361.79% Nov 18, 2022
Credit Suisse
Credit Suisse
Buy
Maintains
$4$4.5
Buy Maintains $4$4.5 +939.02% Nov 15, 2022
Credit Suisse
Credit Suisse
Buy
Initiates
$5
Buy Initiates $5 +1,054.47% Oct 25, 2022
Cowen & Co.
Cowen & Co.
Buy
Initiates
n/a
Buy Initiates n/a n/a Sep 6, 2022